Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial - Report - MDSpire

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial

  • By

  • Xin Wang

  • Ouying Yan

  • Jitao Zhou

  • Feng Wen

  • Yali Shen

  • Zhiping Li

  • Qiu Li

  • Wenling Wang

  • Xiaohong Cai

  • Shisheng Tan

  • Zi Wang

  • Qing Qiao

  • Dan Cao

  • Meng Qiu

  • Jiyan Liu

  • Hongfeng Gou

  • Ming Liu

  • Cheng Yi

  • Yu Yang

  • Qing Zhu

  • Deyun Luo

  • Yaqin Zhao

  • Ye Chen

  • Shang Wang

  • Qiaoli Wang

  • Ke Cheng

  • Min Ren

  • Xin Liu

  • Feng Xu

  • Feng Bi

  • June 15, 2026

  • 0 min

Share

Clinical Report: Comparative Study of Adjuvant Chemoradiotherapy Versus Chemotherapy Following D2 Gastrectomy in Patients with Gastric Cancer

Overview

This study investigates the efficacy of adjuvant chemoradiotherapy (CRT) compared to chemotherapy alone following D2 gastrectomy in patients with gastric cancer. The findings indicate that the addition of CRT did not show a significant increase in disease-free survival compared to chemotherapy alone.

Background

Gastric cancer is a leading cause of cancer-related mortality globally, with a high risk of recurrence post-surgery. D2 gastrectomy is recommended for resectable cases, yet the role of adjuvant radiotherapy remains debated.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • The study was a randomized phase 3 trial conducted at five tertiary hospitals in China.
  • Patients were assigned to either the concurrent CRT arm or the chemotherapy-alone arm in a 1:1 ratio.
  • Induction chemotherapy with the SOX regimen was administered prior to radiotherapy in the CRT arm.
  • The addition of radiotherapy did not show a significant increase in disease-free survival compared to chemotherapy alone.

Clinical Implications

The findings indicate that adding radiotherapy to chemotherapy may not provide additional benefits in terms of disease-free survival for patients post-D2 gastrectomy.

Conclusion

The study contributes to the ongoing discussion regarding the role of adjuvant therapies in gastric cancer treatment.

Related Resources & Content

  1. Gastric Cancer — Impact of Adjuvant Chemoradiotherapy on Survival Outcomes in Gastric Cancer Patients Undergoing D2 Lymphadenectomy, 2012
  2. Gastric Cancer — Comparison of Open and Minimally Invasive Total Gastrectomy Following Neoadjuvant Chemotherapy: Findings from a European Randomized Study, 2020
  3. Gastric Cancer — A European Viewpoint on Comprehensive Lymph Node Dissection in Gastric Cancer Treatment, 2011
  4. Locally Advanced Gastric Cancer: Adjuvant or Perioperative Therapy With D2 Resection, 2025
  5. Gastric Cancer Guideline - American Society for Radiation Oncology (ASTRO), 2025
  6. A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update, 2025
  7. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction, 2001
  8. Current guideline signals on gastric cancer treatment
  9. Gastric Cancer Guideline - American Society for Radiation Oncology (ASTRO)
  10. A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update
  11. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction | New England Journal of Medicine
  12. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine - PubMed
  13. The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial - PMC
  14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial - PubMed

Original Source(s)

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial

  • by Xin Wang, Ouying Yan, Jitao Zhou, Feng Wen, Yali Shen, Zhiping Li, Qiu Li, Wenling Wang, Xiaohong Cai, Shisheng Tan, Zi Wang, Qing Qiao, Dan Cao, Meng Qiu, Jiyan Liu, Hongfeng Gou, Ming Liu, Cheng Yi, Yu Yang, Qing Zhu, Deyun Luo, Yaqin Zhao, Ye Chen, Shang Wang, Qiaoli Wang, Ke Cheng, Min Ren, Xin Liu, Feng Xu, Feng Bi

  • June 15, 2026

Related Content

HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis

Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis

The role of LARP1 in breast cancer progression: from prognosis to immune microenvironment remodeling